Secondary Surgery for Advanced Ovarian Cancer Combined with Primary Immune Thrombocytopenia: A Case Report and Literature Review

doi:10.12280/gjfckx.20200717

Abstract

Abstract:

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease. It is often associated with the presence of platelet antibodies in the body. ITP can be secondary to a variety of benign and malignant diseases, among which cooccurrence with solid tumors is rare, and cooccurrence with ovarian cancer is even rarer. This paper reports a case of advanced ovarian cancer complicated with ITP during the second operation, and reviews the relevant literature, in order to arouse people′s attention and understanding of this disease, and to add experience for the future clinical diagnosis and treatment.

Key words: Primary immune thrombocytopenia, Chemotherapy induced thrombocytopenia, Ovarian neoplasms, Case reports

LIU Yuan, CHEN Si-lu, SONG Kai-rong, LIU Chang, GAO Li, YANG Yong-xiu. Secondary Surgery for Advanced Ovarian Cancer Combined with Primary Immune Thrombocytopenia: A Case Report and Literature Review[J]. Journal of International Obstetrics and Gynecology, 2021, 48(3): 356-360.

Figures/Tables 1

References 17

[1]	Krauth MT, Puthenparambil J, Lechner K. Paraneoplastic autoimmune thrombocytopenia in solid tumors[J]. Crit Rev Oncol Hematol, 2012,81(1):75-81. doi: 10.1016/j.critrevonc.2011.02.004. doi: 10.1016/j.critrevonc.2011.02.004
[2]	Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011,117(16):4190-4207. doi: 10.1182/blood-2010-08-302984. doi: 10.1182/blood-2010-08-302984 pmid: 21325604
[3]	Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia[J]. Int J Hematol, 2018,107(6):615-623. doi: 10.1007/s12185-018-2445-z. doi: 10.1007/s12185-018-2445-z
[4]	Audia S, Mahévas M, Samson M, et al. Pathogenesis of immune thrombocytopenia[J]. Autoimmun Rev, 2017,16(6):620-632. doi: 10.1016/j.autrev.2017.04.012. doi: 10.1016/j.autrev.2017.04.012
[5]	MacDougall KN, Parylo S, Sokoloff A. A Case of Vancomycin-Induced Immune Thrombocytopenia[J]. Cureus, 2020,12(5):e7940. doi: 10.7759/cureus.7940. doi: 10.7759/cureus.7940
[6]	Bhattacharjee S, Banerjee M, et al. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review[J]. SN Compr Clin Med, 2020 Sep 19: 1-11. doi: 10.1007/s42399-020-00521-8. Epub ahead of print. doi: 10.1007/s42399-020-00521-8
[7]	Vayne C, Guéry EA, Rollin J, et al. Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia[J]. J Clin Med, 2020,9(7):2212. doi: 10.3390/jcm9072212. doi: 10.3390/jcm9072212
[8]	Machlus KR, Thon JN, Italiano JE Jr. Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation[J]. Br J Haematol, 2014,165(2):227-236. doi: 10.1111/bjh.12758. doi: 10.1111/bjh.12758
[9]	Stack A, Khanal R, Denlinger CS. Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review[J]. Clin Colorectal Cancer, 2021,20(1):e1-e4. doi: 10.1016/j.clcc.2020. 07.007. doi: 10.1016/j.clcc.2020. 07.007
[10]	Gangi A, Lu SC. Chemotherapy-associated liver injury in colorectal cancer[J]. Therap Adv Gastroenterol, 2020,13:1756284820924194. doi: 10.1177/1756284820924194. doi: 10.1177/1756284820924194
[11]	Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice[J]. BMC Cancer, 2019,19(1):151. doi: 10.1186/s12885-019-5354-5. doi: 10.1186/s12885-019-5354-5 pmid: 30764783
[12]	Kim HD, Boggs DR. A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer[J]. Am J Med, 1979,67(3):371-377. doi: 10.1016/0002-9343(79)90781-2. doi: 10.1016/0002-9343(79)90781-2 pmid: 573065
[13]	Peffault de Latour R, Des Guetz G, Laurence V, et al. Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases[J]. Am J Clin Oncol, 2004,27(4):333-336. doi: 10.1097/01.coc.0000071461.61445.9a. doi: 10.1097/01.coc.0000071461.61445.9a
[14]	Kamesaki T. Autoimmune hemolytic anemia as a paraneoplastic syndrome associated with solid tumors[J]. Rinsho Ketsueki, 2015,56(7):778-784. doi: 10.11406/rinketsu.56.778. doi: 10.11406/rinketsu.56.778
[15]	Reitter S, Knoebl P, Pabinger I, et al. Postoperative paraneoplastic factor VIII auto-antibodies in patients with solid tumours[J]. Haemophilia, 2011,17(5):e889-894. doi: 10.1111/j.1365-2516. 2011.02522.x. doi: 10.1111/j.1365-2516. 2011.02522.x
[16]	Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients[J]. Semin Arthritis Rheum, 2006,35(5):322-332. doi: 10.1016/j.semarthrit.2005.07.003. doi: 10.1016/j.semarthrit.2005.07.003
[17]	中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国医学前沿杂志(电子版), 2020,12(1):51-58. doi: 10.12037/YXQY.2020.01-07. doi: 10.12037/YXQY.2020.01-07